Ion channel loss drives Pyrazinamide resistance in tuberculosis

Tuberculosis treatment relies on a drug called Pyrazinamide (PZA), but scientists have long struggled to explain exactly how PZA kills the bacterium that causes TB and why it sometimes fails. The difficulty stems from PZA’s context-dependent activity: it works under certain conditions but not others, which has hidden both its mode of action and the genetic changes that allow bacteria to survive. To tackle this puzzle, a team led by Alexandre Gouzy turned to a strategy that mimics conditions bacteria face in human hosts. They combined a host-mimicking culture system with broad, modern tools—genome-wide CRISPRi profiling to test gene function across the genome, metabolomics to measure chemical changes inside cells, and comparative genomics to compare bacterial strains. By integrating these approaches, the researchers set out to find genes and pathways that change how Mycobacterium tuberculosis responds to PZA in conditions similar to those in infected people. Their approach was aimed at revealing resistance mechanisms that would be missed by standard laboratory tests and at clarifying the biochemical basis of PZA’s killing effect.

Using the host-mimicking culture system together with genome-wide CRISPRi profiling, metabolomics, and comparative genomics, the team identified a previously unrecognized player in PZA resistance: the ion channel Rv2571c. Their metabolomics work showed that Rv2571c mediates α-ketoglutarate efflux, a movement of a key metabolic molecule out of the bacterial cytoplasm. Under host-relevant acidic conditions, this efflux amplifies PZA-induced cytoplasmic acidification, meaning that Rv2571c activity makes the drug’s acidifying effect stronger inside the cell. Crucially, loss-of-function mutations in Rv2571c reduce that acidification and confer resistance to PZA. These mutations produced resistance both in vitro and in vivo, and comparative genomics revealed that such loss-of-function variants are under positive selection in clinical isolates from patients. Altogether, the data establish an ion channel–mediated resistance mechanism and support cytoplasmic acidification as the basis of PZA killing.

The findings shift how researchers think about Pyrazinamide and resistance in tuberculosis. By pinpointing Rv2571c and showing that its role in α-ketoglutarate efflux controls how strongly PZA acidifies the bacterial cytoplasm, the study defines a concrete molecular pathway that explains why PZA can fail in some infections. Because loss-of-function mutations in Rv2571c are present and selected in clinical isolates, this pathway is not just a laboratory curiosity but a resistance determinant in patients. Practically, this work can guide improved tests to detect PZA resistance by looking for Rv2571c changes and can inform drug development aimed at shortening TB treatment: new strategies might seek to counteract resistance by restoring cytoplasmic acidification or by targeting the ion channel pathway. In short, the study provides both a clearer mechanistic picture and actionable leads for diagnostics and therapies.